{"id":87442,"date":"2013-09-04T12:47:34","date_gmt":"2013-09-04T16:47:34","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/mallinckrodt-pharmaceuticals-continues-efforts-to-fight-medicine-abuse-with-the-partnership-at-drugfree-org.php"},"modified":"2013-09-04T12:47:34","modified_gmt":"2013-09-04T16:47:34","slug":"mallinckrodt-pharmaceuticals-continues-efforts-to-fight-medicine-abuse-with-the-partnership-at-drugfree-org","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/mallinckrodt-pharmaceuticals-continues-efforts-to-fight-medicine-abuse-with-the-partnership-at-drugfree-org.php","title":{"rendered":"Mallinckrodt Pharmaceuticals Continues Efforts to Fight Medicine Abuse with The Partnership\u00ae at Drugfree.org"},"content":{"rendered":"<p><p>    ST. LOUIS--(BUSINESS WIRE)--  <\/p>\n<p>        Mallinckrodt (MNK)    announced today that it will continue its collaboration with    The Partnership at Drugfree.org for a second year in support of    The Medicine Abuse Project. The campaign brings together    families, communities, industry, health care professionals,    educators, law enforcement and government officials to help    save lives by preventing teen medicine abuse. Mallinckrodt is    renewing its support as a Gold Sponsor, extending the Companys    strong commitment to fighting abuse, diversion, and misuse of    powerful pain medications.  <\/p>\n<p>    Mallinckrodt is dedicated to providing safe and effective    medications for the treatment of patients with pain, and    equally committed to collaborating with organizations like The    Partnership at Drugfree.org to curb diversion, misuse, and    abuse, said Mark Trudeau, President and Chief Executive    Officer, Mallinckrodt Pharmaceuticals. Support of The Medicine    Abuse Project is one example of our broad engagement to prevent    medicine abuse and ensure access only to the patients who need    treatment. We think this project has been especially effective,    given the range of stakeholders involved  from public health    officials to community groups to law enforcement  since    collaboration is critical to addressing this vital issue.  <\/p>\n<p>    Medicine abuse is one of the most significant and preventable    adolescent health problems facing our families today, said    Steve Pasierb, President and CEO of The Partnership at    Drugfree.org. The Partnership is grateful for socially    responsible companies like Mallinckrodt whose support has    helped us launch The Medicine Abuse Project and mobilize both    parents and the public to learn about the problem, talk with    their kids about the dangers of misuse and abuse of    prescription drugs, and properly monitor, safeguard, and    dispose of excess prescription drugs in their homes.  <\/p>\n<p>    A recent study by The Partnership for Drugfree.org found that    one in four teens in the U.S. (24 percent) misused or abused a    prescription drug at least once in their lifetime, a 33 percent    increase since 2008. The Medicine Abuse Project aims to reverse    that trend by empowering parents to educate their children on    the risks of abusing medicine, as well as safeguarding and    properly disposing of unused medications.  <\/p>\n<p>    The Projects overarching goal by 2017 is to prevent half a    million teens from abusing medicine. Phase I of the campaign,    launched in September 2012, began raising awareness of the    issue by asking stakeholders to take aPledge against    medicine abuse. To date, more than 7,200 people have taken the    Pledge. Through media and digital engagement, advocacy, and    community outreach efforts, such as National Drug Take-Back    Day, the campaign has reached millions of Americans in an    effort to achieve its goal. For more information, visit    drugfree.org\/MedicineAbuseProject.  <\/p>\n<p>    ABOUT MALLINCKRODT  <\/p>\n<p>    Mallinckrodt is a leading global specialty pharmaceuticals    business that develops, manufactures, markets, and distributes    specialty pharmaceutical products and medical imaging    agents.The Companys Specialty Pharmaceuticals segment    includes branded and generic drugs, and the Global Medical    Imaging segment includes contrast media and nuclear imaging    agents. Mallinckrodt has approximately 5,500 employees    worldwide with direct sales in roughly 50 countries and    distribution in approximately 40 countries. The Companys 2012    revenue totaled $2.1 billion. To learn more about Mallinckrodt,    visit     <a href=\"http:\/\/www.mallinckrodt.com\" rel=\"nofollow\">http:\/\/www.mallinckrodt.com<\/a>.  <\/p>\n<\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Visit link:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/mallinckrodt-pharmaceuticals-continues-efforts-fight-130000824.html;_ylt=A2KJ3CQaZCdSXSsAXbL_wgt.\" title=\"Mallinckrodt Pharmaceuticals Continues Efforts to Fight Medicine Abuse with The Partnership\u00ae at Drugfree.org\">Mallinckrodt Pharmaceuticals Continues Efforts to Fight Medicine Abuse with The Partnership\u00ae at Drugfree.org<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> ST. LOUIS--(BUSINESS WIRE)-- Mallinckrodt (MNK) announced today that it will continue its collaboration with The Partnership at Drugfree.org for a second year in support of The Medicine Abuse Project. The campaign brings together families, communities, industry, health care professionals, educators, law enforcement and government officials to help save lives by preventing teen medicine abuse <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/mallinckrodt-pharmaceuticals-continues-efforts-to-fight-medicine-abuse-with-the-partnership-at-drugfree-org.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[35],"tags":[],"class_list":["post-87442","post","type-post","status-publish","format-standard","hentry","category-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/87442"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=87442"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/87442\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=87442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=87442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=87442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}